BEIJING, May 6, 2011 /PRNewswire-Asia-FirstCall/ --
China Medical Technologies, Inc. (the "Company") (Nasdaq:
CMED), a leading China-based
advanced in-vitro diagnostic ("IVD") company, today announced that
Mr. Sam Tsang, the Company's Chief
Financial Officer will present at Jefferies 2011 Global Healthcare
Conference in New York at
12:45pm on June 7, 2011 and will meet institutional
investors at the conference throughout the date. He will
travel to Boston, Chicago and Los
Angeles to meet institutional investors during the rest of
the week. Mr. David Chung, the
Company's Financial Controller and Ms. Winnie Yam, the Company's Investor Relations
Manager will participate in Bank of America Merrill Lynch HK China
Healthcare Corporate Day in Hong
Kong on June 8, 2011.
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading China-based advanced IVD company using
molecular diagnostic technologies including Fluorescent in situ
Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an
immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay
(ECLIA), to develop, manufacture and distribute diagnostic products
used for the detection of various cancers, diseases and disorders
as well as companion diagnostic tests for targeted cancer drugs.
The Company generates all of its revenues in China through the sale of diagnostic
consumables including FISH probes, SPR-based DNA chips and ECLIA
reagent kits to hospitals which are recurring users of the
consumables for their patients. The Company sells FISH probes and
SPR chips to large hospitals through its direct sales personnel and
ECLIA reagent kits to small and mid-size hospitals through
distributors. For more information, please visit
http://www.chinameditech.com.
|
Contact
|
|
|
|
|
Winnie Yam
|
|
|
Tel: 852-2511-9808
|
|
|
Email: IR@chinameditech.com
|
|
|
SOURCE China Medical Technologies, Inc.